Estimation of the haematological toxicity of minor groove alkylators using tests on human cord blood cells

M. Ghielmini, G. Bosshard, L. Capolongo, M. C. Geroni, E. Pesenti, V. Torri, M. D'Incalci, F. Cavalli, C. Sessa

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

We evaluated the myelotoxicity and the anti-tumor potential of tallimustine, three of its analogues and carzelesin, with melphalan as reference substance. Tallimustine was tested by clonogenic assays on both human bone marrow (BM) and cord blood (hCB) cells, the other compounds on hCB only. The degree of inhibition of the haemopoietic progenitors GM-CFC, CFC-E and BFU-E was evaluated after exposure to different concentrations. The same schedules were tested on five tumour cell lines. We found that the dose-response curves for tallimustine on BM and hCB cells were similar. Carzelesin was shown to be the most potent of the substances tested and to be the one with the best in vitro therapeutic index; of the distamycin analogues, the one bearing an alpha-bromoacrylic group (FCE 25450) had the best index. For melphalan, tallimustine and carzelesin, the concentration inhibiting the growth of 70% of progenitor cells in vitro (ID70) was similar to the concentrations found in the serum of patients treated at the maximum tolerated dose (MTD). We conclude that hCB cells may be used instead of BM cells for in vitro myelotoxicity tests. Therapeutic indexes can be extrapolated from this model and could help in selecting the most promising analogue for further clinical development. The in vitro-active concentrations are similar to myelotoxic concentrations in patients, suggesting a predictive value for the assay.

Original languageEnglish
Pages (from-to)878-883
Number of pages6
JournalBritish Journal of Cancer
Volume75
Issue number6
Publication statusPublished - 1997

Fingerprint

carzelesin
Alkylating Agents
Fetal Blood
Blood Cells
Melphalan
Bone Marrow Cells
Erythroid Precursor Cells
Maximum Tolerated Dose
Tumor Cell Line
Appointments and Schedules
Stem Cells
Bone Marrow
In Vitro Techniques
tallimustine
Therapeutics
Growth
Serum
Neoplasms

Keywords

  • Carzelesin
  • Clonogenic tests
  • Tallimustine
  • Toxicology

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Ghielmini, M., Bosshard, G., Capolongo, L., Geroni, M. C., Pesenti, E., Torri, V., ... Sessa, C. (1997). Estimation of the haematological toxicity of minor groove alkylators using tests on human cord blood cells. British Journal of Cancer, 75(6), 878-883.

Estimation of the haematological toxicity of minor groove alkylators using tests on human cord blood cells. / Ghielmini, M.; Bosshard, G.; Capolongo, L.; Geroni, M. C.; Pesenti, E.; Torri, V.; D'Incalci, M.; Cavalli, F.; Sessa, C.

In: British Journal of Cancer, Vol. 75, No. 6, 1997, p. 878-883.

Research output: Contribution to journalArticle

Ghielmini, M, Bosshard, G, Capolongo, L, Geroni, MC, Pesenti, E, Torri, V, D'Incalci, M, Cavalli, F & Sessa, C 1997, 'Estimation of the haematological toxicity of minor groove alkylators using tests on human cord blood cells', British Journal of Cancer, vol. 75, no. 6, pp. 878-883.
Ghielmini, M. ; Bosshard, G. ; Capolongo, L. ; Geroni, M. C. ; Pesenti, E. ; Torri, V. ; D'Incalci, M. ; Cavalli, F. ; Sessa, C. / Estimation of the haematological toxicity of minor groove alkylators using tests on human cord blood cells. In: British Journal of Cancer. 1997 ; Vol. 75, No. 6. pp. 878-883.
@article{14e7704249e3409bb18f8c1b86cec0d5,
title = "Estimation of the haematological toxicity of minor groove alkylators using tests on human cord blood cells",
abstract = "We evaluated the myelotoxicity and the anti-tumor potential of tallimustine, three of its analogues and carzelesin, with melphalan as reference substance. Tallimustine was tested by clonogenic assays on both human bone marrow (BM) and cord blood (hCB) cells, the other compounds on hCB only. The degree of inhibition of the haemopoietic progenitors GM-CFC, CFC-E and BFU-E was evaluated after exposure to different concentrations. The same schedules were tested on five tumour cell lines. We found that the dose-response curves for tallimustine on BM and hCB cells were similar. Carzelesin was shown to be the most potent of the substances tested and to be the one with the best in vitro therapeutic index; of the distamycin analogues, the one bearing an alpha-bromoacrylic group (FCE 25450) had the best index. For melphalan, tallimustine and carzelesin, the concentration inhibiting the growth of 70{\%} of progenitor cells in vitro (ID70) was similar to the concentrations found in the serum of patients treated at the maximum tolerated dose (MTD). We conclude that hCB cells may be used instead of BM cells for in vitro myelotoxicity tests. Therapeutic indexes can be extrapolated from this model and could help in selecting the most promising analogue for further clinical development. The in vitro-active concentrations are similar to myelotoxic concentrations in patients, suggesting a predictive value for the assay.",
keywords = "Carzelesin, Clonogenic tests, Tallimustine, Toxicology",
author = "M. Ghielmini and G. Bosshard and L. Capolongo and Geroni, {M. C.} and E. Pesenti and V. Torri and M. D'Incalci and F. Cavalli and C. Sessa",
year = "1997",
language = "English",
volume = "75",
pages = "878--883",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Estimation of the haematological toxicity of minor groove alkylators using tests on human cord blood cells

AU - Ghielmini, M.

AU - Bosshard, G.

AU - Capolongo, L.

AU - Geroni, M. C.

AU - Pesenti, E.

AU - Torri, V.

AU - D'Incalci, M.

AU - Cavalli, F.

AU - Sessa, C.

PY - 1997

Y1 - 1997

N2 - We evaluated the myelotoxicity and the anti-tumor potential of tallimustine, three of its analogues and carzelesin, with melphalan as reference substance. Tallimustine was tested by clonogenic assays on both human bone marrow (BM) and cord blood (hCB) cells, the other compounds on hCB only. The degree of inhibition of the haemopoietic progenitors GM-CFC, CFC-E and BFU-E was evaluated after exposure to different concentrations. The same schedules were tested on five tumour cell lines. We found that the dose-response curves for tallimustine on BM and hCB cells were similar. Carzelesin was shown to be the most potent of the substances tested and to be the one with the best in vitro therapeutic index; of the distamycin analogues, the one bearing an alpha-bromoacrylic group (FCE 25450) had the best index. For melphalan, tallimustine and carzelesin, the concentration inhibiting the growth of 70% of progenitor cells in vitro (ID70) was similar to the concentrations found in the serum of patients treated at the maximum tolerated dose (MTD). We conclude that hCB cells may be used instead of BM cells for in vitro myelotoxicity tests. Therapeutic indexes can be extrapolated from this model and could help in selecting the most promising analogue for further clinical development. The in vitro-active concentrations are similar to myelotoxic concentrations in patients, suggesting a predictive value for the assay.

AB - We evaluated the myelotoxicity and the anti-tumor potential of tallimustine, three of its analogues and carzelesin, with melphalan as reference substance. Tallimustine was tested by clonogenic assays on both human bone marrow (BM) and cord blood (hCB) cells, the other compounds on hCB only. The degree of inhibition of the haemopoietic progenitors GM-CFC, CFC-E and BFU-E was evaluated after exposure to different concentrations. The same schedules were tested on five tumour cell lines. We found that the dose-response curves for tallimustine on BM and hCB cells were similar. Carzelesin was shown to be the most potent of the substances tested and to be the one with the best in vitro therapeutic index; of the distamycin analogues, the one bearing an alpha-bromoacrylic group (FCE 25450) had the best index. For melphalan, tallimustine and carzelesin, the concentration inhibiting the growth of 70% of progenitor cells in vitro (ID70) was similar to the concentrations found in the serum of patients treated at the maximum tolerated dose (MTD). We conclude that hCB cells may be used instead of BM cells for in vitro myelotoxicity tests. Therapeutic indexes can be extrapolated from this model and could help in selecting the most promising analogue for further clinical development. The in vitro-active concentrations are similar to myelotoxic concentrations in patients, suggesting a predictive value for the assay.

KW - Carzelesin

KW - Clonogenic tests

KW - Tallimustine

KW - Toxicology

UR - http://www.scopus.com/inward/record.url?scp=0031051013&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031051013&partnerID=8YFLogxK

M3 - Article

C2 - 9062410

AN - SCOPUS:0031051013

VL - 75

SP - 878

EP - 883

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 6

ER -